GABA, Glutamate and Monoamines in a Single Microdialysate Sample


We have recently developed a method to enable simultaneous measurement of GABA, glutamate, dopamine, noradrenaline, 5-HT (and the metabolites of the monoamines) in a single microdialysate sample. This is a major step forwards allowing cost-effective analysis of the effects of drugs on multiple neurotransmitters in the same study.

To see the data please click here

For further information about our microdialysis services please contact us on

David Heal is Invited Speaker at ADHD Congress


One of our Directors, David Heal, was an invited speaker at the fourth congress of UKAAN, the UK Adult ADHD Network, which was held in London, last week. David gave a talk reviewing 'ADHD drugs - pharmacological mechanisms and clinical outcomes' and also participated in the Lilly Symposium at the meeting.

ZDF Model of Type 2 Diabetes and Diabetic Nephropathy


ZDF rats contain a mutation in the fa/fa gene and are widely used as an animal model of type 2 diabetes and other aspects of the metabolic syndrome. RenaSci have recently characterised the diabetic phenotype of ZDF fa/fa rats and investigated whether these animals can be used to model diabetic-associated renal impairment and nephropathy.

Male ZDF fa/fa rats weighed more than control animals (genotype +/+ or +/fa) as expected. Fasting plasma glucose levels markedly increased with age and plasma fructosamine and blood HbA1c levels were increased at Week 19 (of age) confirming the development of diabetes. An OGTT performed during Week 12 demonstrated impaired glucose tolerance and reduced insulin secretion following the glucose challenge (indicating the start of pancreatic failure). Urinary glucose excretion (Week 16) was also markedly increased, consistent with diabetes.

Albuminuria and increased urinary levels of total protein and the clinical markers, TIM-1 and cystatin-C, indicated that by Week 16, some renal damage had occurred. Hyperfiltration was observed at Week 20. Increased glomerular filtration rate is widely used as a precursor marker of progressive diabetic nephropathy. Importantly, when the diabetic ZDF rats were terminated (Week 26), clear histological evidence of diabetic nephropathy was observed.

These findings confirm that this colony of ZDF rats can be used to model type 2 diabetes and diabetes-associated renal impairment and nephropathy.

To see our flyer on the use of ZDF rats as a model of type 2 diabetes please click here

To see the data on impaired renal function and diabetic nephropathy in the diabetic ZDF rats please click here



RenaSci is part of an exciting new European project called 3D-NET (Drug Discovery and Development of Novel Eye Therapeutics; We will be working with leading academic and industry researchers from KalVista Pharmaceuticals (UK); University College Dublin (Ireland), Universidad de Valladolid (Spain), and Gadea Grupo Farmacéutico (Spain) to develop new drugs to treat ocular diseases arising from diabetes. This 4 year project is funded by a €1.66 million Marie Curie Industry-Academia Pathways and Partnerships (IAPP) grant award from the EU Seventh Framework programme. As part of the project we will be evaluating vascular retinal permeability in experimental models of diabetes such as STZ-treated Brown Norway rats. Please contact us for further information about our animal models for assessing the complications of diabetes.

RenaSci Director Becomes FRSC


We are pleased to announce that one of our Directors, Professor David Heal, has recently been made a Fellow of the Royal Society of Chemistry. FRSC is the senior category of membership of the Royal Society of Chemistry which is the world's leading professional organisation for chemical scientists and currently has 49,000 members. David was invited to be a FRSC as an acknowledgment of his extensive experience of drug discovery and development and the contribution he has made to advancing the wider application of chemical science.